Research Programme: anti-cancer therapeutics - Cornerstone Pharmaceuticals/National Cancer InstituteAlternative Names: Emulsiphan anti-cancer therapeutics
Latest Information Update: 15 Mar 2011
At a glance
- Originator Cornerstone Pharmaceuticals; National Cancer Institute (USA)
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 23 Mar 2010 Preclinical trials in Solid tumours in USA (Parenteral)